{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:59:13Z","timestamp":1761544753218,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100025247","name":"North Dakota Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.japh.2023.10.018","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:39:11Z","timestamp":1697801951000},"page":"350-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A call to develop opioid risk assessment programs for implementation in the pharmacy setting"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6094-0835","authenticated-orcid":false,"given":"Alyssa","family":"Hodges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5720-7019","authenticated-orcid":false,"given":"Anna","family":"Skarphol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.japh.2023.10.018_bib1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0025-6196(11)60748-9","article-title":"Issues in long-term opioid therapy: unmet needs, risks, and solutions","volume":"84","author":"Passik","year":"2009","journal-title":"Mayo Clin Proc"},{"author":"Oliva","key":"10.1016\/j.japh.2023.10.018_bib8"},{"key":"10.1016\/j.japh.2023.10.018_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109856","article-title":"Development and validation of an overdose risk prediction tool using prescription drug monitoring program data","volume":"246","author":"Gellad","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2023.10.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109090","article-title":"How prescription drug monitoring programs influence clinical decision-making: a mixed methods systematic review and meta-analysis","volume":"228","author":"Picco","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2023.10.018_bib11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s12913-019-4642-8","article-title":"The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review","volume":"19","author":"Rhodes","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"10.1016\/j.japh.2023.10.018_bib12","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1016\/j.sapharm.2022.07.009","article-title":"Opioid risk stratification in the community pharmacy: the utility of the Opioid Risk Tool","volume":"18","author":"Strand","year":"2022","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"10.1016\/j.japh.2023.10.018_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"author":"Szalavitz","key":"10.1016\/j.japh.2023.10.018_bib16"},{"key":"10.1016\/j.japh.2023.10.018_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109067","article-title":"Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test","volume":"228","author":"Cochran","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.japh.2023.10.018_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235502","article-title":"Evolution and impact of bias in human and\u00a0machine learning algorithm interaction","volume":"15","author":"Sun","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.japh.2023.10.018_bib21","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.japh.2023.10.018_bib24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.sapharm.2019.11.016","article-title":"Program evaluation of the Opioid and naloxone Education (ONE Rx) program using the RE-AIM model","volume":"16","author":"Strand","year":"2020","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"10.1016\/j.japh.2023.10.018_bib25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jamia\/ocx066","article-title":"Automatable algorithms to identify nonmedical opioid use using electronic data: a systematic review","volume":"24","author":"Canan","year":"2017","journal-title":"J\u00a0Am Med Inform Assoc"},{"issue":"3","key":"10.1016\/j.japh.2023.10.018_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.japh.2021.12.003","article-title":"Opioid risk screening: program evaluation from the community pharmacists\u2019 perspective","volume":"62","author":"Frenzel","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"10","key":"10.1016\/j.japh.2023.10.018_bib28","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/jamia\/ocad110","article-title":"A\u00a0call for better validation of opioid overdose risk algorithms","volume":"30","author":"McElfresh","year":"2023","journal-title":"J\u00a0Am Med Inform Assoc"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:54:13Z","timestamp":1761544453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123003412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1544319123003412"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.018","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A call to develop opioid risk assessment programs for implementation in the pharmacy setting","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}